Featured Press Release

  • 11/14/19 6:50 am EST
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Douglas L. Braunstein is stepping down from the Company’s Board of Directors, effective November 14, 2019. Mr. Braunstein joined the Board in 2016 and served on its Compensation Committee. “We wish Doug well and thank him for his many contributions to Eagle. His valuable insights and perspective, together with his broad financial services experience, have helped guide us as we strive to advance bothSee More
  • 11/12/19 6:51 am EST

    -- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 --

    -- Plan to initiate a clinical trial in December for Eagle’s innovative fulvestrant program, which has the potential to result in greater inhibition of estrogen receptors and better outcomes for patients with estrogen receptor-positive breast cancer --

    -- Company returned to 2019 Hajj and enrolled additional EHS patients in its controlled clinical study --

    -- Eagle expects to file a supplement to the current NDA for the treatment of brain damage secondary to nerve agent exposure in the second half of 2020 --

    WOODCLIFF LAKE, N.J--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three- and nine-month periods ended September 30, 2019. Third quarter and recent highlights include: Invested $12 million in research and development and external legal costs to advance Eagle’s pipeline. Eagle’s Japanese marketing partner, SymBio Pharmaceuticals Limited, submitted a New Drug Application (“NDA”) for TREAKISYM, bendamustineSee More
  • 11/12/19 6:50 am EST
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today provided an update on the Company’s program for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”). Eagle is investigating RYANODEX for EHS in addition to current standard of care, which is comprised of body cooling and supportive measures. There is currently no approved drug product for the treatment of EHS. Over theSee More
Business Wire InvestorHQsm